title: Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
abstract: We investigated the effectiveness of the mass measles vaccination campaign in Urmia, Islamic Republic of Iran, by examining the measles IgG seroprevalence and antibody response from paired data before and after the campaign. The overall seropositive rate of 624 subjects aged 5-25 years increased 1 year after the mass vaccination (from 53.0% to 72.3%). A rise in antibody titre occurred in all age groups except the 21-25 years group, which had the highest titre before mass vaccination. On logistic regression analysis, only immune status prior to vaccination was significantly associated with the seroresponse. It may be cost-effective to check antibody titres before mass vaccinations, especially in high vaccine coverage regions with circulating wild virus.
authors.affiliation: Department of Community Medicine, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Islamic Republic of Iran. yekta42@yahoo.com
authors.forename: Z
authors.initials: Z
authors.lastname: Yekta
authors.forename: R
authors.initials: R
authors.lastname: Pourali
authors.forename: M R
authors.initials: MR
authors.lastname: Taravati
authors.forename: S
authors.initials: S
authors.lastname: Shahabi
authors.forename: S
authors.initials: S
authors.lastname: Salary
authors.forename: F
authors.initials: F
authors.lastname: Khalily
authors.forename: A
authors.initials: A
authors.lastname: Farzin
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007492:Iran / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D032541:Mass Vaccination / Q000458:organization & administration*; D008457:Measles / Q000097:blood / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine / Q000276:immunology*; D015397:Program Evaluation; D016036:Seroepidemiologic Studies; D018709:Statistics, Nonparametric
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine